Skip to main content

Inflammatory Bowel Disease with Iron Deficiency and Anemia Clinical Pathway – All Settings

Clinical Pathway for Evaluation and Treatment of Iron Deficiency
and Anemia in Patients with Inflammatory Bowel Disease (IBD)

 
 

Universal Screening for Iron Deficiency and Anemia

  • CBC, reticulocyte count
  • Iron panel
    • Serum iron, TIBC, transferrin, transferrin saturation (TSAT)
  • Ferritin
  • Soluble transferrin receptor (STFR)
  • Active IBD q3mos
  • Inactive IBD q6mos
Iron Deficiency in Relation to Disease Activity
Active IBD
  • Ferritin < 100 µg/L and TSAT < 20%
  • Elevated soluble transferrin receptor
Inactive IBD
  • Ferritin < 30 µg/L
  • Elevated soluble transferrin receptor
 
 
 
 
 
 
 
 
Adequate iron stores,
No anemia
Adequate iron stores,
Anemia
Iron deficiency
with or without anemia
 
 
 
 
 
 
 
 
Inactive IBD
Active IBD

Continue universal screening

Inactive IBD: q6mos
Active IBD: q3mos

Evaluate for other causes of anemia
Assess anemia level
WHO Anemia Severity Range Hgb (g/dL)
Age (yrs) Mild Moderate Severe
< 5 < 11 < 10 < 7
≥ 5 < 11.5 < 11 < 8
12–14 < 12 < 11 < 8
≥ 15 (F) < 12 (M) < 13 < 11 < 8
 
 
 
 
Mild or
non-anemic
Moderate or severe

IV Iron Rationale

 
 
 
 
Review hematologic response to iron
Repeat CBC and reticulocyte in 4 wks
 
 
 
 
Normalization or hgb increase by ≥ 2g/dL from baseline and normalization of iron store
Inadequate hgb or iron store response to iron treatment
  • Prevent Recurrent Iron Deficiency and Anemia
    • Anemia recurs in > 50% of children with IBD within 10–12 mos
    • Recommend q3mo universal screening for 1 yr after correction at minimum
    • Rapid recurrent iron deficiency with or without anemia may be indicative of subclinical disease activity
  • Administer IV Iron if failed or concern for poor adherence to oral regimen
  • Reassess disease activity, blood loss, other causes of anemia
  • Consider hematology referral
Jump back to top